论文部分内容阅读
[目的]探讨经超声脉冲理疗仪穴位导入高乌甲素对癌痛患者的镇痛效果及生活质量的影响.[方法]本院收治的中晚期肿瘤患者98例,按治疗方法的不同分为对照组48例与观察组50例.对照组患者实施常规的癌痛规范化治疗,观察组在常规治疗的基础上联合超声脉冲理疗仪穴位导入高乌甲素辅助镇痛治疗,两组均治疗 7 d.治疗结束后比较两组患者的镇痛效果及生活质量.[结果]治疗后两组的疼痛程度数字评定量表(NRS)评分较治疗前均降低(P <0.05),且观察组NRS评分显著低于对照组(P <0.05).观察组的疼痛缓解总有效率为 90.00％(45/50),显著高于对照组的68.75％(33/48)(P 0.05).治疗后两组的健康状况、自身生存质量主观感受,生理、心理、环境、社会关系领域评分均升高(P <0.05),其中观察组的健康状况主观感受、生理、心理领域评分均高于对照组(P 0.05).[结论]超声波脉冲理疗穴位导入高乌甲素能够显著减轻癌痛患者的疼痛程度,提高患者疼痛缓解率及生活质量.“,”[Objective]To investigate the effects of analgesia and quality of life in patients with cancer pain through acupoint introduction of lappaconitone by ultrasonic pulse therapy instrument . [MethodslA total of 98 patients with advanced stage tumors admitted to our hospital were divided into two groups. Patients (n = 48) in the control group received standardized treatment for cancer pain,and patients (n = 50) in the observation group were treated with ultrasound-guided analgesia on the basis of routine treatment. Both groups received continuous treatment for 7 days . Analgesic effect and quality of life between the two groups were compared.[Results]After treatment, the NRS scores (number rating scale) of the two groups were lower than those before treatment(P <0.05),and the NRS scores in the observation group were significantly lower than in the control group (P <0.05) . The total effective rate of pain relief in the observation group was 90.00％ (45/50), which was significantly higher than that in the control group 68.75％ (33/48, P 0.05) . After treatment, both groups had higher scores in terms of subjective feeling of health condition, quality of life, physiological,psychological, environmental and social relations (P <0.05) . Compared to the control group, the scores of subjective feeling of health condition,physiological and psychological status in the observation group was better (P 0.05).[Conclusion]The introduction of lappaconitone by ultrasonic pulse therapy can significantly reduce the pain level of cancer patient and improve the pain relief rate and quality of life in patients with cancer pain